期刊文献+

司美格鲁肽注射液治疗2型糖尿病患者短期与长期经济学研究系统评价

Short/long-term economic evaluations of Semaglutide Injection for the treatment of patients with type 2 diabetes mellitus
原文传递
导出
摘要 目的:系统评价国内外司美格鲁肽注射液的短期和长期济学研究现状。方法:系统检索PubMed、Embase、Web of Science、Cochrane Library、EBM Reviews-Health Technology Assessment、EBM Reviews-NHS Economic Evaluation Database、中国知网、万方、维普9个数据库及ISPOR网站。检索时间从建库至2023年12月1日。2名研究者独立筛选文献、提取数据和评价质量后进行定性分析。结果:共纳入38篇文献,结果表明在相关研究国家视角下,与其他GLP-1受体激动剂(度拉糖肽、艾塞那肽ER、利拉鲁肽)及甘精胰岛素注射液相比,司美格鲁肽注射液具有经济性;与SGLT-2抑制剂(恩格列净和卡格列净)相比,司美格鲁肽注射液具有长期经济性。结论:仍需开展基于中国人群真实世界数据的各项经济学研究,为利益相关者提供决策依据。 OBJECTIVE To systematically review the short/long-term economic evaluations of Semaglutide Injection.METHODS The databases of PubMed,Embase,Web of Science,Cochrane Library,EBM Reviews-Health Technology Assessment,EBM Reviews-NHS Economic Evaluation Database,China National Knowledge Infrastructure(CNKI),Wanfang,VIP and ISPOR were searched from inception until December 1,2023.Two researchers independently screened reports,extracted raw data and evaluated qualities.RESULTS A total of 38 articles were included.From the perspective of research countries,Semaglutide Injection was economically advantageous compared to other GLP-1 receptor agonists(e.g.dulaglutide,exenatide ER&liraglutide)and insulin glargine.When compared with SGLT-2 inhibitors(empagliflozin&canagliflozin),Semaglutide Injection demonstrated superior long-term economic benefits.CONCLUSION Further economic studies based upon realworld data of Chinese populations are required for providing decision-making references for stakeholders.
作者 保芸 万旭 吴斌 俞萍萍 王立群 BAO Yun;WAN Xu;WU Bin;YU Pingping;WANG Liqun(Gansu Provincial Hospital,Institute of Clinical Research&Evidence-Based Medicine,Gansu Lanzhou 730000,China;Renji Hospital,School of Medicine,Shanghai Jiao Tong University,Department of Pharmacy,Shanghai 200000,China;Renji Hospital,School of Medicine,Shanghai Jiao Tong University,Clinical Research Unit,Shanghai 200000,China;Department of Pharmacy,Ningbo No.2 Hospital,Zhejiang Ningbo 315010,China;Beijing Anzhen Hospital,Capital Medical University,Department of Traditional Chinese Medicine Physiotherapy,Beijing 100000,China)
出处 《中国医院药学杂志》 CAS 北大核心 2024年第14期1675-1682,共8页 Chinese Journal of Hospital Pharmacy
基金 上海申康医院发展中心临床科技创新项目(编号:SHDC12019X10) 兰州市城关区科技计划项目(编号:2018KJGG0036)。
关键词 司美格鲁肽注射液 控制成本分析 成本效果分析 系统评价 Semaglutide Injection cost control analysis cost-effectiveness analysis systematic review
  • 相关文献

参考文献3

二级参考文献6

共引文献721

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部